AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago. The US regulator has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results